Successful Management with Dual Therapy of Lenvatinib and Macitentan for Hepatocellular Carcinoma with Portopulmonary Hypertension

Hepatology ◽  
2021 ◽  
Author(s):  
Tsuyoshi Ishikawa ◽  
Ryo Sasaki ◽  
Takashi Matsuda ◽  
Issei Saeki ◽  
Taro Takami ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Dual Therapy ◽  
Portopulmonary Hypertension ◽  
Successful Management

scholarly journals A Global Review of Hepatocellular Carcinoma (HCC)

2021 ◽  
Vol 68 (1) ◽  
Author(s):  
Gokul V ◽  
Natarajan P ◽  
Vijay J ◽  
Janani A M ◽  
Mumthaj P
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Literature Search ◽  
Management Strategies ◽  
Treatment Schedule ◽  
Successful Management ◽  
The Third ◽  
Molecular Therapies ◽  
Targeted Molecular Therapies ◽  
Enzymatic Pathways

Hepatocellular carcinoma is the leading cause of death in cirrhosis. Hepatocellular carcinoma is the sixth most prevalent cancer and the third most frequent cause of cancer-related death. To review the risk factors, causes, morphology, enzymatic pathways and management strategies involved in hepatocellular carcinoma. A literature search was performed using PubMed for publications with a predetermined search string to identify relevant studies. The diagnosis and treatment schedule used for the successful management of hepatocellular carcinoma. Studies combining sorafenib with locoregional or other targeted molecular therapies are likely to improve responses and outcome.

Comparative effectiveness of combination TACE/ablation vs. monotherapy in hepatocellular carcinoma.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 350-350
Author(s):  
Arthur Winer ◽  
Yohei Rosen ◽  
Frederick Lu ◽  
Russell S. Berman ◽  
Marcovalerio Melis ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Therapy Group ◽  
Dual Therapy ◽  
Treatment Modalities ◽  
Kaplan Meier ◽  
Hazard Ratios ◽  
Treatment Type ◽  
Significant Difference ◽  
Arterial Chemoembolization

350 Background: Hepatocellular Carcinoma (HCC) is a leading cause of cancer-related death worldwide. Loco-regional treatment modalities for HCC include Trans-Arterial Chemoembolization (TACE) and Radiofrequency/Microwave Ablation (RFA/MWA). Studies have shown that dual therapy with both TACE and ablation is beneficial, though data is limited. We retrospectively studied all HCC patients treated with either TACE, ablation, or dual therapy at a tertiary referral public hospital to determine differences in survival. Methods: Following IRB approval, all patients diagnosed with HCC (1998-2013) at our institution were retrospectively analyzed for date of diagnosis, treatment-type, length of follow-up, and survival. Patients were excluded if they did not undergo TACE or RFA/MWA, or underwent other treatments, such as surgery. The primary outcome was all-cause mortality 5 years after diagnosis. Kaplan Meier curves were created and statistics with Log-rank testing and hazard ratios (HR) were performed. Results: Of 509 patients diagnosed with HCC, 109 (21.4%) met inclusion criteria. 60 were treated with TACE alone, 30 with ablation alone, and 19 were treated with both, either concomitantly or in sequence. Median follow-up and overall median survival was 15.5, 19, and 52 months for TACE, ablation, and dual therapy, respectively. Survival at 5 years was 11.9%, 13.3% and 42.1% for TACE, ablation, and combination groups respectively. Kaplan Meier analysis revealed a significant increase in survival in the combination therapy group vs. RFA or TACE alone at 5 years (p = 0.0006). However, there was no significant difference in survival when comparing TACE vs. RFA/MWA at 5 years (HR = 1.18, p = 0.48). Conclusions: Our study suggests a greater survival benefit for patients treated with TACE and RFA/MWA versus either modality alone.

scholarly journals Portopulmonary hypertension: Formidable dual threat versus hopeful dual therapy

2014 ◽  
Vol 20 (6) ◽  
pp. 635-636 ◽  
Author(s):  
Michael J. Krowka ◽  
Rodrigo Cartin-Ceba
Keyword(s):  
Dual Therapy ◽  
Portopulmonary Hypertension

Successful management of portopulmonary hypertension with beraprost

2010 ◽  
pp. 1
Author(s):  
Eui Joo Kim ◽  
Mi-Seung Shin ◽  
Kyong Yong Oh ◽  
Myeong Gun Kim ◽  
Kwen Chul Shin ◽  
...  
Keyword(s):  
Portopulmonary Hypertension ◽  
Successful Management

scholarly journals Successful management of the hepatocellular carcinoma with inferior vena cava tumor thrombus

Medicine ◽  
2021 ◽  
Vol 100 (21) ◽  
pp. e26081
Author(s):  
Yuanjun Liu ◽  
Kunlin Xie ◽  
Jiaxin Li ◽  
Zhi Wang ◽  
Yong Zeng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Inferior Vena Cava ◽  
Tumor Thrombus ◽  
Inferior Vena ◽  
Vena Cava ◽  
Successful Management

Multimodality treatment of hepatocellular carcinoma

1998 ◽  
Vol 13 (11-s4) ◽  
pp. S315-S319 ◽  
Author(s):  
ZHAO-YOU TANG ◽  
XIN-DA ZHOU ◽  
ZENG-CHEN MA ◽  
ZHI-QUAN WU ◽  
JIA FAN ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Multimodality Treatment

Hepatocellular carcinoma

1982 ◽  
Vol 118 (1) ◽  
pp. 69-70 ◽  
Author(s):  
A. J. Bennett
Keyword(s):  
Hepatocellular Carcinoma
Sign in / Sign up

Export Citation Format

Share Document